Yegin Zeynep Arzu, Özkurt Zübeyde Nur, Dikyar Asena, Kaynar Lale Aydın, Karacaoğlu Özlem, Yağcı Münci
Gazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey.
Gazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey.
Transplant Proc. 2021 Jul-Aug;53(6):2013-2020. doi: 10.1016/j.transproceed.2021.06.017. Epub 2021 Jul 8.
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a curable treatment modality for hematologic disorders. Transplant-related mortality remains high despite prominent scientific and technologic improvements. In consideration with the potential impact of patient- and disease-related factors on transplant outcome, this retrospective study was performed to investigate the predictive role of pretransplant HCT-composite risk (HCT-CR) score in allo-HCT recipients.
A total of 313 patients with acute leukemia (male/female: 192/121; median age, 36 [18-71] years) were included in this study. The study cohort was divided into 2 subgroups based on pretransplant HCT-CR categories. The HCT-CR group included low-risk patients, and the HCT-CR group consisted of intermediate-, high-, and very high-risk patients.
In the whole cohort, overall survival (OS) and 5-year OS were found to be 32.2% and 45.1%, respectively. Probability of OS was significantly better in the HCT-CR group compared with the HCT-CR group (P < .001). Leukemia-free survival (LFS) and 3-year LFS were 59.5% and 65.1%, respectively. Probability of LFS was better in the HCT-CR group compared with the HCT-CR group (P = .001). Nonrelapse mortality (NRM) and 3-year NRM were estimated to be 38.1% and 27.5%, respectively. Probability of NRM was significantly higher in the HCT-CR group compared with the HCT-CR group (P = .012). In multivariate analysis, HCT-CR was shown to have significant prognostic impact in acute lymphoblastic leukemia patients (P = .023; hazard ratio, 2.613; 95% CI, 1.142-5.982).
Pretransplant evaluation of patient- and disease-related factors is essential for the accurate prediction of posttransplant survival. Further efforts to evolve current criteria for pretransplant risk assessment would eventuate in better transplant outcomes.
异基因造血干细胞移植(allo-HCT)是治疗血液系统疾病的一种可治愈的治疗方式。尽管在科学技术方面有显著进步,但移植相关死亡率仍然很高。考虑到患者和疾病相关因素对移植结果的潜在影响,本回顾性研究旨在探讨移植前HCT综合风险(HCT-CR)评分在allo-HCT受者中的预测作用。
本研究共纳入313例急性白血病患者(男/女:192/121;中位年龄36[18-71]岁)。根据移植前HCT-CR类别将研究队列分为2个亚组。HCT-CR低危组包括低风险患者,HCT-CR高危组包括中、高和极高风险患者。
在整个队列中,总生存率(OS)和5年OS分别为32.2%和45.1%。与HCT-CR高危组相比,HCT-CR低危组的OS概率显著更好(P<.001)。无白血病生存率(LFS)和3年LFS分别为59.5%和65.1%。与HCT-CR高危组相比(P=.001),HCT-CR低危组的LFS概率更好。非复发死亡率(NRM)和3年NRM分别估计为38.1%和27.5%。与HCT-CR低危组相比,HCT-CR高危组的NRM概率显著更高(P=.012)。在多变量分析中,HCT-CR对急性淋巴细胞白血病患者具有显著预后影响(P=.023;风险比,2.613;95%CI,1.142-5.982)。
对患者和疾病相关因素进行移植前评估对于准确预测移植后生存至关重要。进一步努力改进当前的移植前风险评估标准将带来更好的移植结果。